Psyence Biomedical
8 hedge funds and large institutions have $280K invested in Psyence Biomedical in 2024 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 3 increasing their positions, 1 reducing their positions, and 2 closing their positions.
200% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 1
0% more funds holding
Funds holding: 8 → 8 (0)
0% more ownership
Funds ownership: 0% → 0% (+0%)
0% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 2
66% less capital invested
Capital invested by funds: $831K → $280K (-$551K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AI
AdvisorShares Investments
Bethesda,
Maryland
|
+$153K |
| 2 |
CS
Clear Street
New York
|
+$15K |
| 3 |
Morgan Stanley
New York
|
+$15K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$15K |
| 5 |
HF
HRT Financial
New York
|
+$5.99K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TSS
Two Sigma Securities
New York
|
-$63.6K |
| 2 |
CAC
Cowen and Company
New York
|
-$28.5K |
| 3 |
VF
Virtu Financial
New York
|
-$8.99K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
AI
1
AdvisorShares Investments
Bethesda,
Maryland
| $148K | +$153K | +51 | +70% |
|
|
CF
2
Cantor Fitzgerald
New York
| $101K | – | – | – |
|
|
3
UBS Group
Zurich,
Switzerland
| $6.87K | +$15K | +5 | +500% |
|
|
CS
4
Clear Street
New York
| $6K | +$15K | +5 | New |
|
|
5
Morgan Stanley
New York
| $6K | +$15K | +5 | New |
|
|
HF
6
HRT Financial
New York
| $5K | +$5.99K | +2 | +67% |
|
|
VF
7
Virtu Financial
New York
| $4K | -$8.99K | -3 | -43% |
|
8
Geode Capital Management
Boston,
Massachusetts
| $3.15K | – | – | – |
|
|
HT
9
Headlands Technologies
Chicago,
Illinois
| $8 | – | – | – |
|
10
JP Morgan Chase
New York
| $1 | – | – | – |
|
|
TSS
11
Two Sigma Securities
New York
| – | -$63.6K | -15 | Closed |
|
|
CAC
12
Cowen and Company
New York
| – | -$28.5K | -7 | Closed |
|
PBM Hedge Fund Activity: Q2 2024 in Review
8 of the 6,925 institutional investors tracked by Wall St. Rank reported a position in Psyence Biomedical (PBM) for Q2 2024, worth a combined $280K — down 66% from $831K a quarter earlier.
Fund positioning in PBM was balanced in Q2 2024: 2 funds opened new positions, 2 closed out, 3 added to existing stakes and 1 trimmed.
The largest buyer was AdvisorShares Investments, adding an estimated $153K. The largest seller was Two Sigma Securities, exiting entirely with an estimated $63.6K sold.
- 8 institutional investors held Psyence Biomedical (PBM) as of Q2 2024, unchanged from Q1 2024.
- Funds reported $280K of Psyence Biomedical stock for Q2 2024, down 66% quarter-over-quarter.
- 2 funds opened new Psyence Biomedical positions in Q2 2024 and 2 closed out, a net change of 0 holders.
- The largest Psyence Biomedical buyer in Q2 2024 was AdvisorShares Investments, an estimated $153K added.
- The largest Psyence Biomedical seller in Q2 2024 was Two Sigma Securities, an estimated $63.6K sold.
Based on aggregated 13F filings for Q2 2024.